These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 33048619)

  • 1. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
    Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA;
    J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
    Flaherty KT; Gray R; Chen A; Li S; Patton D; Hamilton SR; Williams PM; Mitchell EP; Iafrate AJ; Sklar J; Harris LN; McShane LM; Rubinstein LV; Sims DJ; Routbort M; Coffey B; Fu T; Zwiebel JA; Little RF; Marinucci D; Catalano R; Magnan R; Kibbe W; Weil C; Tricoli JV; Alexander B; Kumar S; Schwartz GK; Meric-Bernstam F; Lih CJ; McCaskill-Stevens W; Caimi P; Takebe N; Datta V; Arteaga CL; Abrams JS; Comis R; O'Dwyer PJ; Conley BA;
    J Natl Cancer Inst; 2020 Oct; 112(10):1021-1029. PubMed ID: 31922567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
    Parsons DW; Janeway KA; Patton DR; Winter CL; Coffey B; Williams PM; Roy-Chowdhuri S; Tsongalis GJ; Routbort M; Ramirez NC; Saguilig L; Piao J; Alonzo TA; Berg SL; Fox E; Hawkins DS; Abrams JS; Mooney M; Takebe N; Tricoli JV; Seibel NL;
    J Clin Oncol; 2022 Jul; 40(20):2224-2234. PubMed ID: 35353553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
    Meric-Bernstam F; Ford JM; O'Dwyer PJ; Shapiro GI; McShane LM; Freidlin B; O'Cearbhaill RE; George S; Glade-Bender J; Lyman GH; Tricoli JV; Patton D; Hamilton SR; Gray RJ; Hawkins DS; Ramineni B; Flaherty KT; Grivas P; Yap TA; Berlin J; Doroshow JH; Harris LN; Moscow JA
    Clin Cancer Res; 2023 Apr; 29(8):1412-1422. PubMed ID: 36662819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on research activity in the USA on Cancer Precision Medicine.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
    Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
    J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
    Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
    J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
    Zhou I; Plana D; Palmer AC
    Clin Cancer Res; 2024 Feb; 30(4):786-792. PubMed ID: 38109210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
    Hirshfield KM; Tolkunov D; Zhong H; Ali SM; Stein MN; Murphy S; Vig H; Vazquez A; Glod J; Moss RA; Belyi V; Chan CS; Chen S; Goodell L; Foran D; Yelensky R; Palma NA; Sun JX; Miller VA; Stephens PJ; Ross JS; Kaufman H; Poplin E; Mehnert J; Tan AR; Bertino JR; Aisner J; DiPaola RS; Rodriguez-Rodriguez L; Ganesan S
    Oncologist; 2016 Nov; 21(11):1315-1325. PubMed ID: 27566247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan.
    Kato S; Hayashi T; Suehara Y; Hamanoue H; Yamanaka S; Ichikawa Y; Higurashi T; Ohashi K; Yamaguchi S; Nozaki Y; Terao Y; Saito T
    Jpn J Clin Oncol; 2019 Feb; 49(2):174-182. PubMed ID: 30541038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
    Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
    Chen AP; Kummar S; Moore N; Rubinstein LV; Zhao Y; Williams PM; Palmisano A; Sims D; O'Sullivan Coyne G; Rosenberger CL; Simpson M; Raghav KPS; Meric-Bernstam F; Leong S; Waqar S; Foster JC; Konaté MM; Das B; Karlovich C; Lih CJ; Polley E; Simon R; Li MC; Piekarz R; Doroshow JH
    JCO Precis Oncol; 2021; 5():. PubMed ID: 33928209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
    Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
    Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.